Literature DB >> 11501850

Radiation therapy for oncological emergencies.

V Donato1, P Bonfili, N Bulzonetti, M Santarelli, M F Osti, V Tombolini, E Banelli, R M Enrici.   

Abstract

AIMS AND
BACKGROUND: Radiation therapy holds a fundamental role in oncological emergencies such as superior vena cava syndrome, spinal cord compression and endocranial hypertension. The purpose of our study was, by comparing schedules of treatment, to confirm the efficacy of hypofractionated radiation therapy.
METHODS: From January 1994 to December 1998, 43 patients with superior vena cava syndrome, 37 patients with metastatic spinal cord compression and 108 patients with endocranial hypertension secondary to metastasis were treated at our institution. In the group of patients with superior vena cava syndrome, radiotherapy schedules were: 4 Gy x 5 to a total dose of 20 Gy (23 patients) and 3 Gy x 10 to a total dose of 30 Gy (20 patients). In the group of patients with spinal cord compression, radiation schedules were: 3 Gy x 10 to a total dose of 30 Gy (15 patients); 4 Gy x 5 to a total dose of 20 Gy (12 patients); a single fraction of 8 Gy in 10 cases, repeated after 1 week in 7 responder cases to a total dose of 16 Gy. 5 out of 37 patients were underwent to laminectomy plus stabilization of the spine and post-operative radiotherapy. In the group of patients with endocranial hypertension, radiotherapy schedules were: 6 Gy x 2 to a total dose of 12 Gy (53 patients), repeated after 4 weeks in 34 responder patients and 3 Gy x 10 to a total dose of 30 Gy (55 patients).
RESULTS: The patients with superior vena cava syndrome, revaluated after 4 weeks at the end of treatment, obtained a partial remission of symptomatology in 73.9% with 20 Gy and in 75% with 30 Gy. The patients with spinal cord compression obtained symptomatic relief in 73.3% with 30 Gy, in 66.6% with 20 Gy and in 70% of cases treated with 8 Gy. The patients with endocranial hypertension obtained symptomatic relief in 64.1% with 12 Gy and in 63.3% with 30 Gy.
CONCLUSION: Histology, pretreatment and performance status were important prognostic factors for the response to therapy. Our results demonstrated no significant difference among different schedules of radiotherapy and confirmed the importance of radiotherapy for oncological emergencies: it improves the quality of life and, in responding patients, is associated with a longer survival time.

Entities:  

Mesh:

Year:  2001        PMID: 11501850

Source DB:  PubMed          Journal:  Anticancer Res        ISSN: 0250-7005            Impact factor:   2.480


  6 in total

1.  Radiation dose is associated with prognosis of small cell lung cancer with superior vena cava syndrome.

Authors:  Zhen-Bo Wang; Fang-Ling Ning; Xiao-Le Wang; Yu-Feng Cheng; Xin-Jun Dong; Chang-Min Liu; Shao-Shui Chen
Journal:  Int J Clin Exp Med       Date:  2015-03-15

Review 2.  Radiotherapy basics for family physicians. Potent tool for symptom relief.

Authors:  Rajiv Samant; Adrian Chuen Chiang Gooi
Journal:  Can Fam Physician       Date:  2005-11       Impact factor: 3.275

3.  Knowledge and utilization of palliative radiotherapy by pediatric oncologists.

Authors:  T L Tucker; R S Samant; E J Fitzgibbon
Journal:  Curr Oncol       Date:  2010-02       Impact factor: 3.677

4.  Radiotherapy for oncologic emergencies on weekends: examining reasons for treatment and patterns of practice at a Canadian cancer centre.

Authors:  G Mitera; A Swaminath; S Wong; P Goh; S Robson; E Sinclair; C Danjoux; E Chow
Journal:  Curr Oncol       Date:  2009-08       Impact factor: 3.677

5.  How should we describe the benefits of palliative radiotherapy?

Authors:  R Samant; T Tucker
Journal:  Curr Oncol       Date:  2006-12       Impact factor: 3.677

6.  Radiotherapy in oncological emergencies: fast-track treatment planning.

Authors:  Lukas Nierer; Franziska Walter; Maximilian Niyazi; Roel Shpani; Guillaume Landry; Sebastian Marschner; Rieke von Bestenbostel; Dominika Dinkel; Gabriela Essenbach; Michael Reiner; Claus Belka; Stefanie Corradini
Journal:  Radiat Oncol       Date:  2020-09-10       Impact factor: 3.481

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.